On June 24, 2024, Teva announced the launch of an authorized generic for Victoza® (liraglutide injection 1.8mg). Victoza is a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patient 10 years of age and older with type 2 diabetes (T2D) and to reduce the risk of major cardiovascular events (MACEs) in adults with T2D and established cardiovascular (CV) disease. Several manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA, and therefore it is expected that true generics will be available soon. Generic Victoza is not anticipated to significantly impact the GLP-1 RA space due the daily administration requirement and weight loss of 50% or less than once-weekly SC-dosed Ozempic and Mounjaro.
